
LONDON, Sept 16 (Reuters) - A combination treatment from GlaxoSmithkline for melanoma, the deadliest form of skin cancer, has won priority review from U.S. regulators. The move means the Food and Drug Administration will now decide whether to approve the dual use of Tafinlar, also known as
LONDON, Sept 16 (Reuters) - A combination treatment from GlaxoSmithkline for melanoma, the deadliest form of skin cancer, has won priority review from U.S. regulators. GSK said on Monday the Food and Drug Administration had prioritised a review of a combination of dabrafenib and trametinib
COPENHAGEN, Sept 16 (Reuters) - Shares in Danish biotech firm Genmab jumped 8.5 percent at open on Monday after the company said late on Friday the United States Food and Drug Administration (FDA) had granted its leukaemia drug "Breakthrough Therapy Designation". Breakthrough Therapy Desig
ASOS: Panmure Gordon raises target price from 4555p to 5950p maintaining a buy recommendation. AstraZeneca: Jefferies reduces target price from 3200p to 2850p and retains a hold recommendation. Barclays: Jefferies initiates with a target price of 367p and a buy recommendation. Barratt Development
SHANGHAI, Sept 13 (Reuters) - Chinese authorities visited a local office of German drugmaker Bayer AG in late August to investigate a potential case of unfair competition, the company said on Friday. China's regulators have been probing numerous international and Chinese drugs firms, with i
WASHINGTON, Sept 12 (Reuters) - Generic drug companies can develop generic versions of Lovaza, a fish-oil derived drug used to treat high cholesterol, a U.S. appeals court ruled on Thursday. In April 2009, Pronova BioPharma Norge AS filed a patent infringement lawsuit in Delaware against Te
By Adam Jourdan SHANGHAI, Sept 12 (Reuters) - Chinese drug company Sino Biopharmaceutical Ltd has set up a team to investigate allegations broadcast on state television that its majority-owned subsidiary had paid for illegal overseas trips for doctors, it said on Thursday. Regional sa
By Adam Jourdan SHANGHAI, Sept 12 (Reuters) - Chinese drug company Sino Biopharmaceutical Ltd has set up a team to investigate allegations broadcast on state television that its majority-owned subsidiary had paid for illegal overseas trips for doctors, it said on Thursday. Regional sa
* CEO expects shakeout in fragmented consumer health market * Company has firepower to do sizeable deals * RB likely to see disposals as well as acquisitions (Adds more comments, background) By Martinne Geller and Ben Hirschler LONDON, Sept 11 (Reuters) - Reckitt Benckis
Panmure Gordon has kept its positive stance on pharmaceuticals group GlaxoSmithKline, despite recent concerns over rising competition from generic versions of its Advair drug, recommending investors to 'buy' on weakness. The broker said that there are still a number of regulatory process steps and
JOHANNESBURG, Sept 11 (Reuters) - South Africa's Aspen Pharmacare said on Wednesday its full-year earnings rose by a quarter, helped by strong performance at home and overseas, and it was planning a push into Russia. Aspen, Africa's largest maker of generic drugs, said diluted headline earn
By Martinne Geller and Ben Hirschler LONDON, Sept 11 (Reuters) - Reckitt Benckiser Group will be a major player in a coming shakeout of the global consumer health industry and has the capability to do sizeable deals, according to its chief executive. Speaking at the Reuters Consumer
By Adam Jourdan SHANGHAI, Sept 11 (Reuters) - Chinese insulin maker Gan & Lee Pharmaceuticals said on Wednesday it was investigating allegations published in a newspaper that it spent around 800 million yuan ($130.72 million) to bribe doctors to promote the firm's drugs over five years.
Panmure Gordon has kept its positive stance on pharmaceuticals group GlaxoSmithKline, despite recent concerns over rising competition from generic drugs, recommending investors to 'buy' on weakness. GSK's share price sunk 2.5% on Tuesday after the US Food and Drug Administration (FDA) published dra